The AEGEAN trial demonstrated a clinically meaningful improvement in EFS with the addition of perioperative durvalumab to neoadjuvant chemotherapy, alongside significantly improved pathological complete response and major pathological response . Understanding surgical outcomes can further inform the use of this treatment and is an important consideration for patients and physicians,"
The AEGEAN trial is a double-blind, placebo-controlled phase 3 study that evaluated the use of perioperative durvalumab in combination with neoadjuvant chemotherapy compared to neoadjuvant chemotherapy alone. The trial involved adults with treatment-naïve resectable NSCLC and ECOG PS 0/1. Patients were randomized to receive either neoadjuvant durvalumab 1500 mg or placebo intravenously alongside platinum-based CT prior to surgery.
Lobectomy, sleeve resection, or bilobectomy were allowed as planned surgery ; the protocol was amended with enrollment ongoing to exclude patients with tumors classified as T4 for any reason other than size or whose planned surgery was pneumonectomy .
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: medical_xpress - 🏆 101. / 51 Read more »